dutasteride

FDA Drug Profile — AVODART

dutasteride is listed in the FDA National Drug Code directory with 3 NDC codes, marketed under brand name including AVODART. Available dosage forms: capsule, gelatin coated, powder, capsule, liquid filled.

Drug details

Generic Name
dutasteride
Brand Names
AVODART
Application Number
NDA021319
Sponsor
Catalent Pharma Solutions, LLC
NDC Codes
3
Dosage Forms
CAPSULE, GELATIN COATED, POWDER, CAPSULE, LIQUID FILLED
Routes
ORAL
Active Ingredients
DUTASTERIDE

Indications and Usage

1 INDICATIONS AND USAGE Dutasteride is a 5 alpha-reductase inhibitor indicated for the treatment of symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate to: ( 1.1 ) improve symptoms, reduce the risk of acute urinary retention, and reduce the risk of the need for BPH-related surgery. Dutasteride in combination with the alpha-adrenergic antagonist, tamsulosin, is indicated for the treatment of symptomatic BPH in men with an enlarged prostate. ( 1.2 ) Limitations of Use: Dutasteride is not approved for the prevention of prostate cancer. ( 1.3 ) 1.1 Monotherapy Dutasteride capsules are indicated for the treatment of symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate to: improve symptoms, reduce the risk of acute urinary retention (AUR), and reduce the risk of the need for BPH-related surgery. 1.2 Combination with Alpha-adrenergic Antagonist Dutasteride in combination with the alpha-adrenergic antagonist, tamsulosin, is indicated for the treatment of symptomatic BPH in men with an enlarged prostate. 1.3 Limitations of Use Dutasteride is not approved for the prevention of prostate cancer.

Sources: openFDA, FDA Data Dashboard, FDA.gov. Report a data issue: hello@regdatalab.com.